Intraepidermal and subepidermal blistering with skin necrosis, possibly caused by etanercept in treatment of a patient with psoriasis
نویسندگان
چکیده
299 How to cite this article: Abreu Velez AM, Jackson BL, Howard MS. Intraepidermal and subepidermal blistering with skin necrosis, possibly caused by etanercept in treatment of a patient with psoriasis. Our Dermatol Online. 2015;6(3):299-303. Submission: 22.01.2015; Acceptance: 12.03.2015 DOI:10.7241/ourd.20153.80 Intraepidermal and subepidermal blistering with skin necrosis, possibly caused by etanercept in treatment of a patient with psoriasis
منابع مشابه
A Case Report of Treatment of a Wound with Extensive Skin Necrosis Using Modern Dressing in a One-Month-Old Infant
Background and Objectives: A wound is an injury or rupture on the surface of skin, which is caused physically, chemically, mechanically, or by heat. Case Report: The patient was a one-month-old infant who admitted to the hospital with seizure. After physical examination, it was revealed that the left thigh had an extensive skin necrosis due to burn. After the debridement of the lesion, due ...
متن کاملNodular Vasculitis That Developed during Etanercept (Enbrel) Treatment in a Patient with Psoriasis
Nodular vasculitis was introduced by Montgomery for cases of erythema induratum-like lesions that were not associated with tuberculosis. Nodular vasculitis has been associated with both nontuberculous infections and noninfectious conditions. However, there has been no report on the development of nodular vasculitis during tumor necrosis factor-α inhibitor treatment. A 28-year-old man visited ou...
متن کاملEtanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
Etanercept (Enbrel, Amgen and Wyeth), a tumor necrosis factor (TNF) antagonist, was approved in January 2002, for the treatment of psoriatic arthritis (PsA). The anti-inflammatory effects of etanercept are due to its ability to bind to the pro-inflammatory cytokine TNF, preventing it from interacting with cell-surface receptors and rendering it biologically inactive. Etanercept was evaluated fo...
متن کاملInternational Trends in Immunity
Psoriasis is an immune-mediated chronic inflammatory skin disorder, affecting 2–3% of the world population, with roughly one third of the patients suffering from moderate-to-severe disease and a high impact on quality of life. Since Tumor Necrosis Factor (TNF) alpha has been recognized as a pivotal cytokine in the pathogenesis of the disease, treatment of psoriasis has improved considerably wit...
متن کاملEtanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
BACKGROUND Etanercept, a tumour-necrosis-factor inhibitor, has shown efficacy in the treatment of rheumatoid arthritis. Psoriatic arthritis and psoriasis are disease states in which tumour necrosis factor, a proinflammatory cytokine, is present in increased concentrations in joints and in the skin. Therefore, psoriatic arthritis and psoriasis may be appropriate therapeutic targets for etanercep...
متن کامل